In spite of the expression of SSTR (predominantly SSTR5) in a majority of lung adenocarcinomas, there is no evidence for the preventive or therapeutic efficacy of SSAs in this tumor entity. This evidence concerns the gene SSTR5 and lung adenocarcinoma.